Your browser doesn't support javascript.
loading
Phase 1 trial of ADI-PEG20 plus cisplatin in patients with pretreated metastatic melanoma or other advanced solid malignancies.
Yao, Shuyang; Janku, Filip; Subbiah, Vivek; Stewart, John; Patel, Sapna Pradyuman; Kaseb, Ahmed; Westin, Shannon Neville; Naing, Aung; Tsimberidou, Apostolia Maria; Hong, David; Piha-Paul, Sarina Anne; Shi, Nai; Johnston, Amanda; Bomalaski, John; Fu, Siqing.
Afiliación
  • Yao S; Departments of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Janku F; Department of Thoracic Surgery, Xuanwu Hospital, Capital Medical University, Beijing, China.
  • Subbiah V; Departments of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Stewart J; Departments of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Patel SP; Departments of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Kaseb A; Departments of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Westin SN; Departments of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Naing A; Departments of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Tsimberidou AM; Departments of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Hong D; Departments of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Piha-Paul SA; Departments of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Shi N; Departments of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Johnston A; Departments of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Bomalaski J; Polaris Pharmaceuticals, Inc., San Diego, CA, USA.
  • Fu S; Polaris Pharmaceuticals, Inc., San Diego, CA, USA.
Br J Cancer ; 124(9): 1533-1539, 2021 04.
Article en En | MEDLINE | ID: mdl-33674736
Asunto(s)
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Protocolos de Quimioterapia Combinada Antineoplásica / Terapia Recuperativa / Melanoma / Neoplasias Tipo de estudio: Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: Br J Cancer Año: 2021 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Protocolos de Quimioterapia Combinada Antineoplásica / Terapia Recuperativa / Melanoma / Neoplasias Tipo de estudio: Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: Br J Cancer Año: 2021 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Reino Unido